Literature DB >> 26229143

Current Status of Nuclear Medicine Practice in Latin America and the Caribbean.

Diana Páez1, Pilar Orellana2, Claudia Gutiérrez3, Raúl Ramirez4, Fernando Mut5, Leonel Torres6.   

Abstract

The practice of nuclear medicine (NM) in the Latin American and Caribbean region has experienced important growth in the last decade. However, there is great heterogeneity among countries regarding the availability of technology and human resources. According to data collected through June 2014 by the International Atomic Energy Agency (IAEA), the total number of γ cameras in the region is 1,231, with an average of 2.16 per million inhabitants. Over 90% of the equipment is SPECT cameras; 7.6% of which have hybrid technology. There are 161 operating PET or PET/CT cameras in 12 member states, representing a rate of 0.3 per million people. Most NM centers belong to the private health system and are in capitals or major cities. Only 4 countries have the capability of assembling 99Mo-99mTc generators, and 2 countries produce 99mTc from nuclear reactors. Cold kits are produced in some countries, and therapeutic agents are mostly imported from outside the region. There are 35 operative cyclotrons. In relation to human resources: there is 1 physician per γ camera, 1.6 technologists per γ camera, 0.1 medical physicist per center, and approximately 0.1 radiochemist or radiopharmacist per center. Nearly 94% of the procedures are diagnostic. PET studies represent about 4% of the total. The future of NM in the Latin American and Caribbean region is promising, with great potential and possibilities. Some of the most important factors driving the region toward greater homogeneity in the availability and application of NM, and bridging the gaps between countries, are clinician awareness of the importance of NM in managing diseases prevalent in the region, increased building of capacity, continuous and strong support from international organizations such as the IAEA through national and regional projects, and strong public-private partnerships and government commitment.
© 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  Latin America; PET; SPECT; nuclear medicine; radionuclides

Mesh:

Substances:

Year:  2015        PMID: 26229143     DOI: 10.2967/jnumed.114.148932

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

1.  Head to head comparison performance of 99mTc-EDDA/HYNIC-iPSMA SPECT/CT and 68Ga-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patients.

Authors:  Francisco Osvaldo García-Pérez; Jenny Davanzo; Sergio López-Buenrostro; Clara Santos-Cuevas; Guillermina Ferro-Flores; Miguel A Jímenez-Ríos; Anna Scavuzzo; Zael Santana-Ríos; Sevastián Medina-Ornelas
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-10-20

2.  Opportunities for improvement on current nuclear cardiology practices and radiation exposure in Latin America: Findings from the 65-country IAEA Nuclear Cardiology Protocols cross-sectional Study (INCAPS).

Authors:  João V Vitola; Fernando Mut; Erick Alexánderson; Thomas N B Pascual; Mathew Mercuri; Ganesan Karthikeyan; Nathan Better; Madan M Rehani; Ravi Kashyap; Maurizio Dondi; Diana Paez; Andrew J Einstein
Journal:  J Nucl Cardiol       Date:  2016-02-22       Impact factor: 5.952

3.  Current status of nuclear cardiology practice in Latin America and the Caribbean.

Authors:  Diana Paez; Amalia Peix; Pilar Orellana; Joao Vitola; Fernando Mut; Claudia Gutiérrez; Crosby Plaza; Tarik Becic; Maurizio Dondi; Enrique Estrada
Journal:  J Nucl Cardiol       Date:  2016-08-29       Impact factor: 5.952

4.  Comparison of 18F-NaF PET/CT with Other Imaging Methods in the Detection of Bone Metastases in Patients with Medullary Thyroid Cancer: a Report of a Series of 31 Cases.

Authors:  Cristina Emiko Ueda; Paulo Schiavom Duarte; Luciana Audi de Castroneves; George Barbério Coura-Filho; Heitor Naoki Sado; Marcelo Tatit Sapienza; Ana Oliveira Hoff; Carlos Alberto Buchpiguel
Journal:  Nucl Med Mol Imaging       Date:  2020-09-28

5.  Clinicopathology and treatment of a giant malignant phyllodes tumor of the breast: A case report and literature review.

Authors:  Wayne A Warner; Vandana Devika Sookdeo; Maurice Fortuné; Meenakshi Akhilesh; Chalapathi Rao Adidam Venkata; Wayne Mohammed; Cassandra Ramkissoon; Dave Harnanan; Lemuel Pran; Ravi Maharaj
Journal:  Int J Surg Case Rep       Date:  2017-10-04

6.  Synthesis and Evaluation of Novel Norfloxacin Isonitrile 99mTc Complexes as Potential Bacterial Infection Imaging Agents.

Authors:  Si'an Fang; Yuhao Jiang; Di Xiao; Xuran Zhang; Qianqian Gan; Qing Ruan; Junbo Zhang
Journal:  Pharmaceutics       Date:  2021-04-09       Impact factor: 6.321

7.  Regulation of nuclear medicine services: Perception of the problems and challenges in Colombia for the approach to cancer

Authors:  Eliana Marcela Murcia; Johana Andrea Lineros; Jairo Aguilera; Carlos Eduardo Granados; María Cristina Martínez; Nathaly Barbosa
Journal:  Biomedica       Date:  2021-12-15       Impact factor: 0.935

8.  Prospective testing of clinical Cerenkov luminescence imaging against standard-of-care nuclear imaging for tumour location.

Authors:  Magdalena Skubal; Benedict Mc Larney; Pamela Causa-Andrieu; Edwin C Pratt; Sudeep Das; Peter Sawan; Abdallah Araji; Christopher Riedl; Kunal Vyas; David Tuch; Jan Grimm
Journal:  Nat Biomed Eng       Date:  2022-04-11       Impact factor: 29.234

Review 9.  Medical imaging and nuclear medicine: a Lancet Oncology Commission.

Authors:  Hedvig Hricak; May Abdel-Wahab; Rifat Atun; Miriam Mikhail Lette; Diana Paez; James A Brink; Lluís Donoso-Bach; Guy Frija; Monika Hierath; Ola Holmberg; Pek-Lan Khong; Jason S Lewis; Geraldine McGinty; Wim J G Oyen; Lawrence N Shulman; Zachary J Ward; Andrew M Scott
Journal:  Lancet Oncol       Date:  2021-03-04       Impact factor: 41.316

Review 10.  Brain SPECT as a Biomarker of Neurodegeneration in Dementia in the Era of Molecular Imaging: Still a Valid Option?

Authors:  Rodolfo Ferrando; Andres Damian
Journal:  Front Neurol       Date:  2021-05-10       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.